ACRP GCP and Clinical Trial Principles Practice Test

These questions are part of the practice quiz. Start practicing

• In a trial, what is the purpose of screening?
• Which regulatory framework does the ACRP exam base on?
• How should data integrity issues be handled?
• Can a CRC obtain informed consent?
• What is source data in clinical trials?
• What practices support IP accountability at trial sites?
• What is the ethical foundation document for human subject research?
• How would you classify a protocol violation?
• What should be done with data queries?
• Which elements are typically included in informed consent to help the subject decide whether to participate?
• What is a typical duration for trial-record retention after completion?
• Is memorization alone sufficient for the ACRP exam?
• Which statement best describes data integrity across the study lifecycle?
• What are the three core ethical principles?
• In remote trials, which approach best supports data integrity and oversight?
• Which document supports evaluation of trial conduct and data quality?
• What is assent?
• Which documents are considered essential to initiation of a trial?
• What does ALCOA+ add?
• An audit is best described as which of the following?
• Can research begin without IRB approval?
• What must be given to the subject after signing consent?
• Which statement about Case Report Form (CRF) is true?
• What must delegation show?
• What is an Adverse Event (AE)?
• What does data integrity mean in the context of clinical research?
• Which statement best describes SUSAR?
• Who is responsible for safeguarding participant rights and welfare?
• What consent form must be used?
• Must an AE be related to study drug?
• Which option would be an example of a primary endpoint in a clinical trial?
• What does post-trial access refer to?
• How do remote or decentralized trials maintain GCP compliance?
• What is an audit?
• What is the Investigational Product (IP) responsible for at the site level?
• Which statement about exam preparation is accurate?
• For non-life-threatening SUSAR, the reporting deadline is:
• Can a PI delegate responsibility?
• Which statement about delegation of tasks is true?
• What is the primary purpose of ICH-GCP Guideline E6?
• What is the purpose of the Trial Master File (TMF)?
• How should a sponsor address suspected misconduct or data fabrication?
• In GCP, which practice is essential to upholding respect for persons?
• Under GCP, which is a key obligation when enrolling participants?
• What is 'risk-based monitoring'?
• Must consent be in a language the subject understands?
• Which of the following best describes the main data-privacy considerations in a clinical trial?
• What best defines informed consent in clinical trials?
• What is quality by design?
• Which statement best defines ALCOA?
• Which statement best describes the Investigator's responsibility in a clinical trial?
• Which term best describes an Investigational Product (IP) in a trial?
• What is the sponsor's primary role regarding trial quality?
• Data handling should be performed how when a data query arises?
• Under what condition is re-consent required when new risk information becomes available?
• What do inclusion and exclusion criteria specify?
• What is the IRB/IEC's role in a trial?
• What does SDV stand for?
• What actions should be taken if a protocol amendment affects subject safety?
• Which party is responsible for ensuring correct form and documentation related to consent?
• What constitutes a Serious Adverse Event (SAE)?
• How must delegation be documented?
• Which of the following is true about AE causality assessment?
• In pediatric trials, which role provides consent for the child?
• What is the primary purpose of Source Data Verification (SDV)?
• What does respect for persons mean?
• For life-threatening or fatal SUSAR, by when must regulatory authorities be informed?
• CBC measures which components of blood?
• Which step best describes what a CRC must do after identifying an adverse event?
• Who is primarily responsible for safeguarding participant rights and welfare?
• Who designs the protocol?
• What is the CRC's role in the informed consent process?
• What does Source Data Verification (SDV) involve?
• What is risk-based monitoring?
• How is blinding defined in a clinical trial?
• If new information arises that changes risk/benefit, what should happen regarding consent?
• Who approves the Protocol before a trial begins?
• Who are considered vulnerable populations?
• Which documents are typically part of essential documents for initiation?
• What must be included in an informed consent form to comply with GCP?
• Which factor determines the retention period for study records?
• Who provides consent for minors?
• What is a key aspect of recruitment that protects participants?
• How are ACRP exam questions structured?
• What is source data verification?
• What is a Serious Adverse Event (SAE)?
• How would you classify a protocol deviation?
• What is informed consent?
• Informed consent is best described as which of the following?
• Which statement best describes how long study records must be retained?
• What is the typical timeframe to report an SAE from awareness to sponsor?
• What is the sponsor's obligation regarding insurance in clinical trials?
• What is the primary purpose of Good Clinical Practice (GCP)?
• What best defines sponsor-investigator responsibility?
• When should informed consent be obtained?
• SUSAR differs from a general SAE because it is
• When preparing for monitors' visits, what should the CRC do?
• What is a Case Report Form (CRF)?
• What happens to the Trial Master File (TMF) after a study is completed?
• What does blinding accomplish in a trial?
• Which statement about delegation is true?
• Which statement best describes essential documents for initiation?
• Is data fabrication ever allowed?
• In relation to data integrity, what does the CRC ensure?
• When must informed consent be obtained?
• What is an Investigational Product (IP)?
• Which scenario would be classified as an SAE?
• Which category of documents shows trial conduct and data quality and includes approvals, CVs, and the Trial Master File?
• What is the primary focus of ICH E6 (R3)?
• Who selects investigators?
• What is a primary objective of recruitment ethics?
• Which option best describes a deviation in a protocol?
• What ensures personnel stay competent in GCP over time?
• Which sequence best addresses suspected misconduct?
• Who manages day-to-day trial operations?
• Which items must subjects understand before consenting?
• Which practice is effective for reducing bias by assignment?
• What does "quality by design" emphasize in ICH E6 (R3)?
• Name a population category that requires additional protections in trials?
• What basic lab concept does CBC measure?
• Which statement marks the conclusion of a clinical trial?
• Who bears the ultimate responsibility for the conduct of a clinical trial at a site?
• What is randomization?
• How is pediatric assent handled in minors participating in a trial?
• Which statement is true regarding IRB responsibilities?
• What is de-identification in data protection?
• Who determines AE causality?
• What takes priority in clinical research?
• Does the ACRP exam test FDA regulations?
• How should protocol amendments be implemented?
• A protocol deviation becomes a protocol violation when:
• Which item is NOT typically part of IP accountability at sites?
• What does justice mean?
• What does ALCOA stand for?
• What is an audit in clinical research?
• Can a PI delegate trial tasks?
• What are 'Essential Documents' in GCP?
• Which action is advised when a protocol amendment affects safety?
• What document provides clinically relevant information about the investigational product to investigators and assessors?
• Which features are essential for an Electronic Data Capture (EDC) system's security?
• What constitutes adequate personnel GCP training?
• Why are regulatory submissions necessary for a trial?
• Which version of ICH E6 is referenced for 2025 exams?
• If a new risk or new information affects a participant's participation, what action is required?
• How does the CRC interact with monitors?
• When is re-consent required?
• What is the purpose of randomization concealment?
• What is the role of informed consent in a trial regarding participant information?
• What does final data lock signify?
• Which guideline governs GCP?
• What is bias?
• What is the CRC's role in AE/SAE reporting?
• What is a primary endpoint?
• Is the CRC responsible for subject safety?
• Which document records who is authorized to perform specific trial tasks?
• What is a typical trial-record retention period?
• What is a protocol deviation?
• What is blinding?
• Which statement about the exam is true?
• How do you distinguish a deviation from a violation?
• What does IP stand for and what is its primary responsibility?
• In data integrity, what is the CRC responsible for?
• Who has overall responsibility for trial conduct at the site?
• How do you choose the BEST answer on the ACRP exam?
• Which principle ensures fair distribution of the burdens and benefits of research?
• What are essential documents?
• Which statement about source data is true?
• If a protocol violation is discovered after data analysis, which steps should be taken?
• Who has primary responsibility for subject safety in a trial?
• Which elements are described in a protocol?
• What is the primary responsibility of a monitor?
• Is informed consent a one-time event?
• Who supervises the research team?
• What document outlines the trial's objectives, design, methods, and statistical approach and must be approved by the ethics committee?
• What does beneficence mean?
• What is a protocol?
• What is the primary role of the IRB?
• Which principle requires fair and equitable subject selection?
• Who performs monitoring?